- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Prof. Mitsudomi on Perioperative Therapy for Resectable NSCLC with Actionable Genetic Alterations
Prof. Tetsuya Mitsudomi, M.D., Izumi City General Hospital, Kindai University, outlines the forthcoming strategies in the management of resectable NSCLC.
Prof. Tetsuya Mitsudomi, M.D., Ph.D., President, Izumi City General Hospital; Professor, Kindai University; Former President, IASLC (2019–2021); Associate Editor, Journal of Thoracic Oncology, iscusses the next steps in managing resectable non-small cell lung cancer (NSCLC) with actionable genetic alterations (AGAs). He emphasizes that while AGAs are typically responsive to targeted inhibitors, treatment efficacy can vary based on several factors. Prof. Mitsudomi highlights the innovative role of perioperative targeted therapies in optimizing outcomes and stresses the need for further clinical trials to refine and personalize treatment approaches.
Видео Prof. Mitsudomi on Perioperative Therapy for Resectable NSCLC with Actionable Genetic Alterations канала MedJ
Prof. Tetsuya Mitsudomi, M.D., Ph.D., President, Izumi City General Hospital; Professor, Kindai University; Former President, IASLC (2019–2021); Associate Editor, Journal of Thoracic Oncology, iscusses the next steps in managing resectable non-small cell lung cancer (NSCLC) with actionable genetic alterations (AGAs). He emphasizes that while AGAs are typically responsive to targeted inhibitors, treatment efficacy can vary based on several factors. Prof. Mitsudomi highlights the innovative role of perioperative targeted therapies in optimizing outcomes and stresses the need for further clinical trials to refine and personalize treatment approaches.
Видео Prof. Mitsudomi on Perioperative Therapy for Resectable NSCLC with Actionable Genetic Alterations канала MedJ
Комментарии отсутствуют
Информация о видео
23 апреля 2025 г. 6:42:27
00:30:06
Другие видео канала
MedJ Takes You to WCLC 2025 - David Planchard
Prof. Liu and Prof. Peters Discuss Treatment Efficacy for Mutation - Positive Lung Cancer Patients.
2025 AAD: Meet with Prof.Hassan Galadari, ADC President
MedJ at ERS 2025- Winfried Randerath
Prof. Yemima Berman: The Frontier of Neurofibromatosis Diagnosis and Treatment!
Prof. Marina Chiara Garassino on the progress and future of targeted combination therapies in NSCLC
2025 AAD: Meet With Dr. Susan C. Taylor, President Elect of the AAD
NEODORA Trial & EGFR+ NSCLC: Dr. Thomas Stinchcombe on Evolving Perioperative Strategies
Prof. Karim Fizazi Interprets the First Results of the PEACE-2 Trial
Professor Kohei Shitara at ASCO 2025 -- MedJ Interview
Post-2025 ASCO Sharing: Prof. Fred Hirsch on Advances in Targeted Therapy Research
Prof. Marina Chiara Garassino on the Best Treatment Initial Therapy for Lung Cancer
Professor Nicolas Girard at ASCO 2025 -- MedJ interview
Prof. Enrique Gallardo on Final Overall Survival Results of Enzalutamide Plus Radium-223 in mCRPC
Prof. Solange Peters on Five Strategies to Extend Survival in Oncogene-driven NSCLC
Professor Yelena Y. Janjigian at ASCO 2025 -- MedJ Interview
Prof. Yan and Prof. Peters Debate TKI and Chemotherapy Combinations in Lung Cancer Treatment.
Prof. Shen and Prof. Hendriks on how to choose from new adjunvant TKI and Chemotherapy for NSCLC.
Dr. George R. Thompson Shares "Approach to the Treatment of Invasive Aspergillosis"
Reversing Type 2 Diabetes: Insights from Prof. Roy Taylor
